| case report | Q2782326 |
| scholarly article | Q13442814 |
| P2093 | author name string | Enrique Grande Pulido | |
| Joan Manel Gasent Blesa | |||
| Vicente Alberola Candel | |||
| Juan Laforga Canales | |||
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| Gonadal expression of c-kit encoded at the W locus of the mouse | Q50803430 | ||
| Angiogenetic protooncogene ets-1 induced neovascularization is involved in the metastatic process of testicular germ cell tumors. | Q53376658 | ||
| Expression of the mRNA for the ligand of c-kit in mouse Sertoli cells | Q67688860 | ||
| Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease | Q77214174 | ||
| Stem cell factor receptor (c-KIT) codon 816 mutations predict development of bilateral testicular germ-cell tumors | Q79317172 | ||
| Inhibition of tyrosine kinases PDGFR and C-Kit by imatinib mesylate interferes with postnatal testicular development in the rat | Q80810852 | ||
| The biology of VEGF and its receptors | Q27860704 | ||
| The activated macrophage colony-stimulating factor (CSF-1) receptor as a predictor of poor outcome in advanced epithelial ovarian carcinoma | Q31851169 | ||
| Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study | Q33359841 | ||
| Kinase inhibitors in cancer therapy: a look ahead | Q33897202 | ||
| Role of tyrosine kinase inhibitors in cancer therapy | Q34432091 | ||
| Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies | Q34564857 | ||
| Regulation and targets of receptor tyrosine kinases | Q35045439 | ||
| Flt3 receptor tyrosine kinase as a drug target in leukemia | Q35794059 | ||
| The vascular endothelial growth factor family and its receptors | Q35913133 | ||
| Sunitinib: from rational design to clinical efficacy | Q36747062 | ||
| Aberrant platelet-derived growth factor alpha-receptor transcript as a diagnostic marker for early human germ cell tumors of the adult testis | Q37679463 | ||
| Neovascularization in clinical stage A testicular germ cell tumor: prediction of metastatic disease. | Q40388352 | ||
| CSF-1 and its receptor in ovarian, endometrial and breast cancer | Q40520354 | ||
| RET tyrosine kinase and medullary thyroid cells are unaffected by clinical doses of STI571. | Q40608959 | ||
| Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells | Q40809633 | ||
| Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor. | Q41181353 | ||
| Microvascular pericytes express platelet-derived growth factor-beta receptors in human healing wounds and colorectal adenocarcinoma. | Q42050115 | ||
| Differential expression of the c-kit proto-oncogene in germ cell tumours. | Q42513650 | ||
| SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo | Q44280921 | ||
| In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. | Q44285254 | ||
| Alterations of the c-kit gene in testicular germ cell tumors | Q44490297 | ||
| KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors | Q45151889 | ||
| The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels | Q45194202 | ||
| Bevacizumab plus high-dose ifosfamide, etoposide and carboplatin (HD-ICE) as third-line salvage chemotherapy induced an unexpected dramatic response in highly platinum refractory germ-cell cancer | Q46761398 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 234-241 | |
| P577 | publication date | 2009-12-11 | |
| P1433 | published in | Case reports in oncology | Q27722654 |
| P1476 | title | Final Report of the First Refractory Germ Cell Tumor Treated with Sunitinib Malate | |
| P478 | volume | 2 |
| Q34544846 | Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial |
| Q38341798 | Testicular choriocarcinoma: a rare variant that requires a unique treatment approach |
Search more.